Life Sciences

  • October 16, 2026

    Suing The Trump Admin Can Have Massive Impact, Attys Say

    Lawyers representing clients against the federal government spoke Friday about the challenges and rewards of such litigation in the Trump era, with plaintiff-side powerhouse Elizabeth Cabraser pointing to the potential for massive impact, including one case in which she successfully got more than a billion dollars in grant funding reinstated.

  • October 16, 2026

    Device Co. Accused Of Shorting Co-Founder's Payments

    The co-founder of a company that sells medical devices told a Colorado state court Thursday that the company lowered the percentage he is owed of $7.7 million in outstanding receivables from a client without approval.

  • October 16, 2026

    Quarterly IPO Volume Fell Short Of Expectations Amid Delays

    Third-quarter capital markets activity in the U.S. proved to be robust with a solid string of initial public offerings, but capital markets attorneys say it did not fully meet expectations due to delays of notable IPOs caused by market uncertainty.

  • October 16, 2026

    FTC Wants More Info On $350M Surgical Supplies Deal

    The Federal Trade Commission has requested additional information about MiMedx Group Inc.'s planned $350 million purchase of Sanara MedTech Inc., a company that develops and commercializes products for use during surgery.

  • October 16, 2026

    City Therapeutics' Upsized $200M IPO Joins Biotech Wave

    Blood clot-focused biotechnology firm City Therapeutics began trading publicly Friday after raising $200 million in its upsized initial public offering steered by Goodwin Procter LLP and Cooley LLP, joining a wave of biotechnology public listings over the past few weeks.

  • October 16, 2026

    Could A Criminal Sentencing Case Upend Loper Bright?

    U.S. Supreme Court Justice Neil Gorsuch is concerned that a ruling instructing trial courts to defer to the U.S. Sentencing Commission's interpretation of federal sentencing guidelines could blow a "pretty big hole" in the court's recent rejection of deference doctrines. His colleagues, however, don't appear as perturbed.

  • October 16, 2026

    States Win 1st OK Of $400M Sandoz Generic Price-Fixing Deal

    A Connecticut federal judge granted preliminary approval Friday to a $400 million settlement between a coalition of states, Sandoz Inc. and its subsidiary Fougera Pharmaceuticals Inc. over allegations of generic drug price-fixing and market allocation, setting aside $280 million as restitution.

  • October 16, 2026

    Contradictory Contract Dooms Pot Co.'s Injunction Bid

    A California state judge has rejected a cannabis genetics company's bid for an injunction against a former business partner in a contract dispute, saying the contract's self-contradictory provisions make it unclear that the company is entitled to retrieve its cannabis strains.

  • October 16, 2026

    EpicentRx, Ex-Secretary Clash In Del. Over 5th Contempt Bid

    EpicentRx's former corporate secretary urged the Delaware Chancery Court on Friday to impose a partial default judgment against the biotechnology firm and appoint a receiver, arguing it has continued to ignore advancement and contempt orders. Meanwhile, the company countered that those remedies would be disproportionate to what it says is ultimately a dispute over unpaid money.

  • October 16, 2026

    Taxation With Representation: Freshfields, Morgan Lewis

    In this week's Taxation With Representation, Penske Automotive Group Inc. agrees to be taken private by Motown Acquisition Corp., a GTCR-led group of private investment firms acquires software firm CCC Intelligent Solutions Holdings Inc. and a Steris PLC subsidiary buys specialty surgical products business Xodus Medical Inc.

  • October 16, 2026

    Expect These Post-Midterm Probes If The Hill Changes Hands

    The top investigative priorities of a potentially Democratic-controlled Congress are coming into sharper focus with the midterms weeks away and could impact an array of companies and individuals in technology, finance and energy, experts say.

  • October 16, 2026

    Mayer Brown Lands 2 Sheppard FDA Partners

    Mayer Brown LLP has bolstered its life sciences capabilities with two former Sheppard partners, including that firm's former U.S. Food and Drug Administration practice leader.

  • October 16, 2026

    Mayne Settles US Patent Suit With Teva Over Generic Imvexxy

    ASX-listed Mayne Pharma announced on Friday another settlement related to its oestradiol vaginal insert Imvexxy, with medicines maker Teva Pharmaceuticals USA Inc. agreeing not to enter the U.S. market with a generic version until 2032.

  • October 15, 2026

    OptumHealth Can't Get Out Of PBM Cases In Opioid MDL

    The healthcare delivery arm of UnitedHealth Group's Optum division can't escape bellwether cases alleging pharmacy benefit managers contributed to the opioid epidemic, an Ohio federal judge ruled Thursday, finding a recent Sixth Circuit decision didn't alter the court's jurisdiction over related state-law claims.

  • October 15, 2026

    OrbiMed Closes 2 Latest Funds With Combined $3B In Tow

    Healthcare-focused investment firm OrbiMed on Thursday revealed that it has secured $3 billion of investor commitments across its two latest private equity funds.

  • October 15, 2026

    Medical AI Platforms Report Settlement Amid Discovery Battle

    Medical artificial intelligence startup OpenEvidence and competitors Doximity Inc. and Pathway Medical Inc. told a Massachusetts federal judge on Thursday that they have reached a settlement in principle to resolve a contentious lawsuit and counterclaim.

  • October 15, 2026

    PhRMA Again Seeks To Join 340B Rebate Pilot Fight

    The Pharmaceutical Research and Manufacturers of America on Thursday asked a Maine federal court to let it join a lawsuit challenging the Trump administration's proposed rebate system in the 340B drug discount program, arguing the litigation could directly affect its members' approved plans and financial interests.

  • October 15, 2026

    For 2nd Time, PTAB Won't Invalidate Claims In DNA Patent

    The Patent Trial and Appeal Board has once again found that Guardant Health couldn't show that claims in a University of Washington DNA sequencing patent that had been part of a $245 million infringement judgment were invalid.

  • October 15, 2026

    Calif. Pot Shop Escapes Suit Over Alleged Gummy Reaction

    A California appeals court threw out a man's fraud and unfair competition claims against a cannabis dispensary that sold him a gummy he said induced a panic attack, saying his complaint fails to indicate the dispensary or its employee knowingly misled him.

  • October 14, 2026

    Boies Schiller Adds Ex-DOJ Civil Division Leader In NY, DC

    Boies Schiller Flexner LLP has added a former deputy assistant attorney general in the U.S. Department of Justice's Civil Division to its global investigations and white collar teams in New York and Washington, D.C., according to an announcement made Wednesday.

  • October 14, 2026

    10th Circ. Backs Asset Freeze In SEC Case Against Biotech

    The Tenth Circuit on Wednesday backed a lower court's order freezing a biotech firm's assets in a suit brought by the U.S. Securities and Exchange Commission accusing the company and its founders of misappropriating roughly $9 million.

  • October 14, 2026

    Genentech Wins Judge's OK Of $18M Novartis Award

    A D.C. federal judge has enforced a nearly $18 million arbitral award against Novartis Pharma AG following its dispute with biotechnology firm Genentech Inc. over a licensing agreement for an eye medication.

  • October 14, 2026

    Cannabis Reform Foes Cite GAO In Push To Reopen Hearings

    A U.S. Drug Enforcement Administration administrative law judge on Wednesday ordered the government to respond to a bid by opponents of cannabis reform to reopen hearings on a proposal to loosen federal restrictions on marijuana.

  • October 14, 2026

    Anthropic Seeks To Dodge AI Patent Suit From U. of Tenn.

    Anthropic says it shouldn't have to face a lawsuit accusing it of infringing a pair of patents related to neural networks owned by a research arm of the University of Tennessee because its Claude artificial intelligence tool isn't covered by the patents.

  • October 14, 2026

    LG Says It Doesn't Owe Insurer For Range Fire Damage

    LG Electronics USA Inc. doesn't owe an insurer for coverage it paid to a pair of homeowners after the cooktop burner on their LG electric range allegedly caused a fire, LG said in an answer to an insurer complaint removed to North Carolina federal court.

Expert Analysis

  • Series

    Ballet Makes Me A Better Lawyer

    Author Photo

    A lifetime of learning and performing ballet taught me that success — whether in dance or practicing law — comes only through hours of thorough preparation, boundless energy and relentless effort, says Sharon Katz-Pearlman at Greenberg Traurig.

  • Fed. Circ. In July: Meeting The Enablement Requirement

    Author Photo

    The Federal Circuit's decision in Wyeth v. AstraZeneca last month exemplifies when a generalized conception of an invention is insufficient to enable the full scope of asserted patent infringement claims, and may lead to more enablement challenges, say attorneys at Knobbe Martens.

  • Series

    Taekwondo Makes Me A Better Lawyer

    Author Photo

    Taekwondo has taught me to recognize when to fight for a position and when to focus on finding a solution, and that the best outcomes are often achieved by solving problems — all of which has improved my work as a bankruptcy lawyer, mediator and Subchapter V trustee, says Amy Denton Mayer at Berger Singerman.

  • Why AI Diligence Is Especially Key In IP Practice

    Author Photo

    In light of recent federal court sanctions against intellectual property litigators for filing work product generated by artificial intelligence without verification, it's important to consider the unique risks and consequences that can arise from overreliance on AI, which poses less visible risks in IP matters, says Stephen Ball at Husch Blackwell.

  • How 'Most Favored Nation' Regime Affects Biopharma Deals

    Author Photo

    As M&A activity surges in the biopharma space, companies will need to account for the Trump administration's most-favored-nation pricing proposals — durable in concept, if unsettled in detail — when drafting deals, say attorneys at Gibson Dunn.

  • What To Know As Legal Duty To Consider AI Takes Shape

    Author Photo

    While the U.K. Jurisdiction Taskforce’s recent statement on liability for artificial intelligence harms is nonbinding for both U.K. and U.S. lawyers, it highlights the importance of being able to distinguish between the availability of a tool and a professional obligation to use it, say Jonny Frank and Michael Costa at StoneTurn.

  • NC Dental Review Change Counters Tougher National Trend

    Author Photo

    North Carolina’s elimination of its prior review requirement for dental management agreements departs sharply from the national trend toward expanded corporate practice of medicine oversight, but stakeholders should not view this regulatory shift as a relaxation of compliance expectations, say attorneys at Holland & Knight.

  • NY Bill Would Boost Litigation Risk For Cosmetics Cos.

    Author Photo

    The Beauty Justice Act, now pending in the New York Legislature, would not only present compliance challenges for companies making cosmetics and personal care products, but could also be used by private plaintiffs to bring consumer fraud, false advertising, toxic exposure and product liability claims, says Kadeejah Kelly-Previl at Faegre Drinker.

  • How To Structure Protective Order AI Provisions In IP Disputes

    Author Photo

    A survey of protective orders in recent intellectual property litigation reveals best practices for drafting provisions on artificial intelligence use that maximize IP protection while balancing enforceability with efficient discovery, say Matthew Stephens and Bryce Tabbut at MoFo.

  • Appellate Vape Rulings May Expand State Regulation Powers

    Author Photo

    Two recent federal appeals courts decisions rejecting Federal Food, Drug and Cosmetic Act preemption challenges to state electronic nicotine delivery systems directory laws signal an emerging appellate consensus that could significantly expand states' power to regulate vaping product sales where federal enforcement falls short, say attorneys at Troutman.

  • 5 Lessons For VC Investors From Del. IPO Ruling

    Author Photo

    The Delaware Court of Chancery's recent dismissal of Rostov v. Alcon Research, a derivative action over a proposed initial public offering, provides multiple practice pointers for venture capital investors, including the importance of precisely worded corporate documents and pleading a coherent theory of corporate harm, says Ben Dubin at VC Expert Services.

  • Fed. Circ. Rulings Emphasize Adjudicative Access And Review

    Author Photo

    Decisions from the Federal Circuit's 2026 docket indicate that the court is increasingly paying attention to whether tribunals possess authority to act, meaning practitioners will need to properly address procedural hurdles before they can argue the merits of a case, say attorneys at Reichman Jorgensen.

  • Series

    Being In A Band Made Me A Better Lawyer

    Author Photo

    Playing shows in storied New York City venues and rehearsing with my bandmates in poorly ventilated rooms helped develop the professional qualities I rely on as a litigator, including an ability to collaborate with strong-minded equals and the determination to treat each client with singular focus, says Eliad Shapiro at Herrick Feinstein.

  • 10th Circ. Ruling Undermines False Ad 'Two Clicks' Rule

    Author Photo

    The Tenth Circuit’s recent ruling in KetoNatural Pet Foods v. Hill's Pet Nutrition substantially challenges a long-standing assumption that a company can avoid responsibility for promotional claims simply because the consumer encountered them by clicking a hyperlink to a third-party website, say attorneys at Venable.

  • How Drug Trial Prediction Markets Pose Insider Trading Risks

    Author Photo

    Multiple prediction market platforms have recently announced plans to offer event contracts related to clinical trial outcomes and regulatory decisions, creating new insider trading risks by expanding the group of people possessing related material nonpublic information far beyond traditional corporate insiders, say attorneys at King & Spalding.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.